Verrucous plaque on the foot

Journal of Cutaneous Pathology

Volumn 31, Issue 3, 2004, Pages 271-273

  Arroyo, Martha P ^a,c   Chu, David H ^a   Mobini, Narciss ^b   Park, Henry S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c Dermatology Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ATENOLOL; DIGOXIN; INTERFERON; ISOSORBIDE DINITRATE; NEPHROCAPS; UNCLASSIFIED DRUG;

AGED; AMELANOTIC MELANOMA; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; FOOT AMPUTATION; FOOT DISEASE; HUMAN; LABORATORY TEST; MALE;

AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FOOT; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA, AMELANOTIC; SKIN NEOPLASMS; WARTS;

EID: 1242338022     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0303-6987.2003.00185.x     Document Type: Article

References (15)

1. Adler MJ, White CR Jr. Amelanotic malignant melanoma. Semin Cutan Med Surg 1997; 16: 122.
2. Tschen JA, Fordice DB, Reddick M, Stehlin J. Amelanotic melanoma presenting as inflammatory plaques. J Am Acad Dermatol 1992; 27: 464.
3. Elmets CA, Ceilley RI. Amelanotic melanoma presenting as a pyogenic granuloma. Cutis 1980; 25: 164.
4. Southerland CC, Wasserman LM, Ostapchuk AP. Clinical presentation of pedunculated, amelanotic melanoma: on the plantar aspect. J Foot Surg 1991; 30: 72.
5. Holder JE, Colloby PS, Fletcher A, Camp RD. Amelanotic superficial spreading malignant melanoma mimicking Bowen's disease. Br J Dermatol 1996; 134: 519.
6. Koch SE, Lange JR. Amelanotic melanoma: the great masquerader. J Am Acad Dermatol 2000; 42: 731.
7. Gibson LE, Goellner JR. Amelanotic melanoma: cases studied by Fontana stain, S-100 immunostain, and ultrastructural examination. Mayo Clin Proc 1988; 63: 777.
8. Orlow SJ, Hearing VJ, Sakai C, et al. Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. Proc Natl Acad Sci USA 1995; 92: 101526.
9. Giuliano AE, Cochran AJ, Morton DL. Melanoma from an unknown primary site and amelanotic melanoma. Semin Oncol 1982; 2: 442.
10. Perniciaro C. Dermatopathologic variants of malignant melanoma. Mayo Clin Proc 1997; 72: 273.
11. Elder D, Elenitsas R, Jaworsky C, Johnson B Jr. Histopathology of the Skin, 8th edn. Lippincott-Raven, 1997; pp. 41.
12. Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Join Committee on Cancer Staging System for cutaneous melanoma. J Clin Oncol 2001; 19: 3635.
13. Sober AJ, Chuang T-Y, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001; 45: 579.
14. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon-α-2b adjuvant therapy of high-risk resected cutaneous melanoma. J Clin Oncol 1996; 14: 7.
15. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon-α-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358: 866.